FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy

The U.S. Food and Drug Administration (FDA) granted accelerated approval to atezolizumab and pembrolizumab in April and May 2017, respectively, for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin‐containing chemotherapy. These app...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzman, Daniel L., Agrawal, Sundeep, Ning, Yang‐min, Maher, V. Ellen, Fernandes, Laura L., Karuri, Stella, Tang, Shenghui, Sridhara, Rajeshwari, Schroeder, Jason, Goldberg, Kirsten B., Ibrahim, Amna, McKee, Amy E., Pazdur, Richard, Beaver, Julia A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Regulatory Issues: FDA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459239/
https://www.ncbi.nlm.nih.gov/pubmed/30541754
http://dx.doi.org/10.1634/theoncologist.2018-0084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459239/
https://www.ncbi.nlm.nih.gov/pubmed/30541754
http://dx.doi.org/10.1634/theoncologist.2018-0084

Ejemplares similares